Trial Profile
A Phase I, Multi-Center, Open Label, Safety and Tolerability Study of Single and Repeated Administrations of Escalating Dose(s) of NV1FGF Administered by Intra-Muscular Injection in Patients With Severe Peripheral Artery Occlusive Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Riferminogene pecaplasmide (Primary)
- Indications Peripheral arterial disorders; Peripheral arterial occlusive disorders
- Focus Adverse reactions
- Sponsors Sanofi
- 05 Jun 2014 New trial record